



International Society for Cutaneous Lymphomas

ISCL Cutaneous Lymphoma Symposium

At the 2018 International Investigative Dermatology (IID) Meeting

Wednesday/May 16, 2018

1:30pm-4:30pm

Orlando, Florida, USA

Rosen Shingle Creek Resort; Meeting Room: Panzacola G2/F3/F4

ISCL Program Committee: Joan Guitart-CHAIR, Martine Bagot, Larisa Geskin, Sam Hwang, Ramon Pujol, Gary Wood

Refining and Redefining Blood Involvement in MF/SS

- 1:30-1:40 **Welcome & Introduction**
The American Clinician's Perspective
Joan Guitart, MD, FAAD, Program Chair and ISCL President
Chief of Dermatopathology in the Department of Dermatology; Professor of Dermatology and Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- 1:40-2:25 **State-of-the-Art Lecture: The Hematopathologist's Perspective**
Fiona E. Craig, MD, Professor of Laboratory Medicine and Pathology, Mayo Clinic Arizona, USA
- 2:25-2:35 **The European Perspective**
Julia Scarisbrick, MBChB, FRCP, MD, Consultant Dermatologist, University Hospital Birmingham, U.K.
- 2:35-2:40 **Q&A and Discussion**
- 2:40-2:45 **ISCL General Membership Business Meeting**
- 2:45-3:00 **Coffee Break**

Cutaneous Lymphoma Foundation Young Investigator Award and Presentation

- 3:00-3:15 **Skin Commensals as Instigators of Cutaneous T Cell Lymphoma**, Carina Dehner

Abstracts Presentations

8 minutes for presentation + 2 minutes for Q&A and change of speaker

- 3:15-3:25 **BET inhibition markedly inhibits CTCL cell viability and is synergistically potentiated by BCL2 or HDAC inhibition**, Sa Rang Kim, #452
- 3:25-3:35 **Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma**, Lei Zhao, #400
- 3:35-3:45 **Gentian violet induces pro-apoptotic and anti-proliferative effects in cutaneous T-cell lymphoma (CTCL): Preclinical studies**, Jianqiang Wu, #423

- 3:45:3:55 **Targeting the vitamin B6 pathway as a novel therapeutic strategy for cutaneous T-cell lymphoma**, Cynthia Chen, #163
- 3:55:4:05 **Sézary syndrome patient-derived xenografts for 21-color flow cytometry immunophenotyping and CART cell therapeutic testing**, Karl Staser, #441
- 4:05:4:15 **PUVA and maintenance treatment in mycosis fungoides: Systemic aberrant cytokine expression is a predictor of outcome**, Pablo Vieyra-Garcia, #579
- 4:15-4:25 **Successful identification of copy number variations using next generation sequencing with a tumour panel in plaque/tumour mycosis fungoides**, J Yoo, #146
- 4:25-4:35 **Differences in the miRNA expression profiles of erythrodermic Mycosis Fungoides and Sézary Syndrome**, Anne Hald Rittig, #473

Visit www.cutaneouslymphoma.org for more information about the ISCL and membership!